Detect & monitor pulmonary infections in less than 10 minutes.
The Avisa BreathTestTM is the world's first point of care biomarker system that analyzes exhaled breath to detect & monitor pulmonary infection.Learn How
Empiric therapy for pneumonia rules the day, because physicians do not have timely information, patients are prescribed broad-spectrum antibiotics in a “one-size-fits all”.
This promotes antibiotic resistance, unnecessary hospitalization resulting in secondary bacterial infections and high cost to the heathcare system.
The only test that can differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.
Value-Based, Cost Advantaged Product is a Win for Patient, Doctor, Hospital and PayerLearn More About Clinical Applications
|Turnaround Time < 10 minutes|
|Non-Sputum Producing Patients|
Disease prevalence estimates obtained from literature
Including US, Europe, Japan, China
Indications for use tested in interviews with physicians, respiratory therapists, insurance plan chief medical officers and Avisa medical advisory board.
Large U.S. hospital that admits 1,000 pneumonia patients/year in the emergency department could save up to $4.8 million/year in unnecessary hospital admissions.
President & CEO, Co-Founder
SVP, Technology Development
Co-founder of the Company